Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of biotechnology company ZIOPHARM Oncology (NASDAQ:ZIOP) popped about 10% today after its quarterly results topped Wall Street expectations.

So what: The stock has rebounded solidly over the past several months on an improving outlook, and today's bottom line beat -- Q4 loss of just $0.09 per share versus Wall Street's view of a $0.15 loss -- only reinforces that positive momentum. Management also noted how its clinical oncology candidate Ad-RTS-IL-12 continues to demonstrate strong potential, giving analysts plenty of good vibes over its growth going forward.

Now what: Management said it also expects to file several investigational new drug applications for novel, multigenic gene therapies through 2015. "Working with our partner Intrexon Corporation, we made extensive progress in 2013 toward expanding, and demonstrating the transformative potential of, what is a game-changing technology platform," said CEO Jonathan Lewis, M.D., Ph.D. "This progress will continue in 2014, where we expect to achieve clinical milestones with lead candidate Ad-RTS-IL-12, continue to advance several, cutting edge new product candidates to the clinic, and potentially secure key partnerships." Given ZIOPHARM's very speculative nature and alarmingly high short ratio, however, average investors would probably do well to stay on the sidelines. 

More reliable ways to build wealth
One of the dirty secrets that few finance professionals will openly admit is the fact that dividend stocks as a group handily outperform their non-dividend-paying brethren. The reasons for this are too numerous to list here, but you can rest assured that it's true. However, knowing this is only half the battle. The other half is identifying which dividend stocks in particular are the best. With this in mind, our top analysts put together a free list of nine high-yielding stocks that should be in every income investor's portfolio. To learn the identity of these stocks instantly and for free, all you have to do is click here now.

Brian Pacampara has no position in any stocks mentioned, and neither does The Motley Fool. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Compare Brokers